论文部分内容阅读
目的观察分析使用喹硫平治疗帕金森症伴有精神症状患者的临床疗效。方法从我院2011年5月~2013年4月收治的帕金森症伴有精神症状患者中随机抽取100例作为研究对象,随机分为实验组与对照组,两组均实施常规治疗,实验组加用喹硫平治疗,对照组相应服用安慰剂,对比观察两组临床疗效。结果实验组患者治疗第八周末精神病量表BPRS评分显著下降,P300电位测定N2、P3潜伏期明显缩短,P3波幅明显升高,相比对照组,P<0.05,差异有统计学意义。结论在帕金森伴精神症状患者的临床治疗中使用喹硫平,能够有效改善患者的精神症状,具有理想的临床治疗效果及推广意义。
Objective To investigate the clinical efficacy of quetiapine in patients with Parkinson’s disease and psychiatric symptoms. Methods A total of 100 patients with Parkinson’s disease and psychiatric symptoms admitted to our hospital from May 2011 to April 2013 were randomly divided into experimental group and control group. Both groups were given routine treatment. The experimental group Plus quetiapine treatment, the control group taking placebo, comparative observation of two groups of clinical efficacy. Results The score of BPRS in psychiatry scale in the experimental group decreased significantly at the end of the eighth week. The latency of N2 and P3 in P300 potentiometry was significantly shortened and the amplitude of P3 was significantly increased. Compared with the control group, the difference was statistically significant. Conclusions The use of quetiapine in the clinical treatment of patients with psychiatric symptoms in Parkinson’s disease can effectively improve the patients’ mental symptoms and has ideal clinical therapeutic effect and promotion significance.